Research programme: lipid encapsulated cytarabine - LiPlasome Pharma

Drug Profile

Research programme: lipid encapsulated cytarabine - LiPlasome Pharma

Latest Information Update: 25 Feb 2011

Price : $50

At a glance

  • Originator LiPlasome Pharma
  • Class Arabinonucleosides; Pyrimidine nucleosides
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 25 Feb 2011 Formulation development is ongoing in Denmark
  • 08 Jun 2004 Preclinical trials in Cancer in Denmark (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top